IMA402 + chemotherapy + monoclonal antibody

IMA402 + chemotherapy + monoclonal antibody is an investigational combination regimen being evaluated for the treatment of PRAME-positive solid tumors. The primary component, IMA402, is a next-generation, half-life extended bispecific T cell engaging receptor (TCER®) molecule developed by Immatics. It is designed to target a peptide derived from the Preferentially Expressed Antigen in Melanoma (PRAME) presented by HLA-A*02:01. By binding both the PRAME-HLA complex on tumor cells and the CD3 receptor on T cells, IMA402 redirects T cell cytotoxicity toward the cancer cells. The combination with chemotherapy and a monoclonal antibody is being investigated in Phase Ib/II clinical trials (NCT05958121) to potentially enhance anti-tumor activity in patients with recurrent or refractory solid tumors, including cutaneous and uveal melanoma, ovarian cancer, lung cancer, uterine cancer, and synovial sarcoma.